Swiss ask French to stay neutral
This article was originally published in The Tan Sheet
Executive Summary
Novartis "takes note of the invitation by the Aventis Supervisory Board to enter into negotiations regarding a potential transaction," firm says in an April 2 statement. The invitation was one of two conditions outlined by the Swiss firm to be met before entering into merger talks (1"The Tan Sheet" March 29, 2004, p. 5). The second condition was for the French government to "assume a neutral position." Novartis says it expects the Aventis board to "clarify with the French Government the importance of such a transaction for the shareholders of Aventis as well as its benefits for employment and for research and development"...
You may also be interested in...
Novartis/Aventis Consumer Products Combo Would Be Divested
Novartis would spin-off a combination of its consumer health products and Aventis' older drugs if the two companies were to merge
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.